# A Randomized Controlled Trial of Neoadjuvant Weekly Paclitaxel Versus Weekly Paclitaxel Plus Weekly Carboplatin In Women With Large Operable or Locally Advanced, Triple Negative Breast Cancer

> **NCT03168880** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Tata Memorial Hospital** · enrollment: 720 (actual)

## Conditions studied

- Triple Negative Breast Cancer

## Interventions

- **DRUG:** Paclitaxel + Carboplatin
- **DRUG:** Paclitaxel only

## Key facts

- **NCT ID:** NCT03168880
- **Lead sponsor:** Tata Memorial Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2010-04
- **Primary completion:** 2025-11-30
- **Final completion:** 2025-11-30
- **Target enrollment:** 720 (ACTUAL)
- **Last updated:** 2025-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03168880

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03168880, "A Randomized Controlled Trial of Neoadjuvant Weekly Paclitaxel Versus Weekly Paclitaxel Plus Weekly Carboplatin In Women With Large Operable or Locally Advanced, Triple Negative Breast Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03168880. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*